Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic
The front-runner coronavirus vaccine appears to protect people from symptomatic disease.
After being diagnosed with internal melanoma, Gail decided to undergo a clinical trial of an experimental combination.
My latest scan results were stable, but we weren’t celebrating. Here’s why.
Some experts want to hold out for a more optimal vaccine. Others believe accepting the best possible vaccine sooner than later is ideal.
BO-112 helped make tumor cells more vulnerable to immunotherapy, offering a possible treatment route for hard-to-treat cancers.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
The best-performing combo, firsocostat and cilofexor, showed benefits despite missing the main study endpoint.
Jamil Rivers, 42, is the board president of METAvivor, a nonprofit breast cancer organization. She is living with metastatic breast cancer.
None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.
The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.
The HIV protease inhibitor combination did not speed recovery or reduce the risk of death in a large study.
The treatment reduced coronavirus levels and sped up recovery in a clinical trial.
The 30% improvement in survival has brought a Phase III trial to an early halt.
The trial will test the drug acalabrutinib in those with acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.